Meissa Vaccines has reported that its intranasal Covid-19 vaccine, MV-014-212, generated a robust nasal Immunoglobulin A (IgA) antibody response in seropositive and seronegative adults in Phase I clinical trial.

The live attenuated vaccine is built on the recombinant respiratory syncytial virus (RSV) AttenuBlock platform of Meissa.

It has been designed to be well-attenuated, genetically stable and optimised to offer strong and long-lasting immunity.

The latest initial results are from an interim analysis conducted on 49 subjects.

Of the doses ranging from 10^3-10^5 PFU analysed in the trial, the 10^5 PFU dose stimulated nasal IgA antibody levels that were in line with natural immunity to Covid-19 infection.

The safety data at all the tested dose levels of the vaccine showed MV-014-212 is greatly attenuated, without any infectious vaccine virus seen in trial subjects.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Furthermore, no serious adverse events linked to the vaccine were observed so far.

Currently, the Phase I trial is underway enrolling subjects with full data anticipated next year.

Meissa Vaccines chief medical officer Robert Walker said: “The preliminary clinical data indicate a single, adjuvant-free, needle-free dose of Meissa’s Covid-19 intranasal vaccine can stimulate a nasal IgA antibody response similar to that seen after SARS-CoV-2 infection, with an important difference – safety.

“We will continue to advance Meissa’s Covid-19 intranasal vaccine in this Phase I clinical trial in adults, and we plan to evaluate it as a booster to complement injectable vaccines and initiate a Phase I paediatric study next year.”

The vaccine induced both mucosal and systemic antibodies and demonstrated greater protection against wild-type SARS-CoV-2 challenge in nonhuman primates in preclinical studies.

In addition, serum antibodies were found to neutralise wild-type SARS-CoV-2, as well as the Beta and Alpha variants of the virus.